SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Myriad Genetics, Inc. (MYGN)

NEW YORK, March 15, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or the "Company") (NASADAQ: MYGN). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mygn.

The investigation concerns whether Myriad and certain of its officers and/or directors have violated Federal Securities Laws.

On March 12, 2018, post-market, Myriad disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with "an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid."  On this news, Myriad's share price fell $4.01, or 12.14%, to close at $29.01 on March 13, 2018.

If you are aware of any facts relating to this investigation, or purchased Myriad shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/mygn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC